![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 281, Issue 1, 297-303, 1997
Department of Pharmacology, Vanderbilt University School of
Medicine, Nashville, Tennessee
Many small oligopeptides are rapidly excreted unchanged into bile,
which requires vectorial transport across the hepatocyte. To
characterize the involved carrier system(s) at the canalicular membrane, studies were undertaken with vesicle preparations from the
rat and the model pseudohexapeptide ditekiren. The initial uptake rate
into inside-out-oriented vesicles was found to be ATP- and
temperature-dependent and saturable. Kinetic analysis indicated the
involvement of three processes: (1) an ATP-dependent carrier-mediated
process (Km = 19.1 ± 4.26 µM;
mean ± S.E.M.), Vmax = 140 ± 29.4 pmol/mg of protein/15 sec), (2) an ATP-independent carrier-mediated transporter (Km = 17.2 ± 9.58 µM, Vmax = 62.9 ± 24.5 pmol/mg of protein/15 sec) and (3) a nonsaturable component. ATP-dependent uptake was inhibited by several other oligopeptides, which in the case of EMD 51921 was competitive.
Cis-inhibition studies with known substrates for the
canalicular bile salt (taurocholate), multispecific organic anion
(glutathione disulfide) and P-glycoprotein (daunomycin, nicardipine,
cyclosporin A) transporters indicated a major role for the latter
carrier system. Inhibition of the initial uptake rate of ditekiren by
daunomycin was found to be competitive in nature
(Ki = 16 µM). These findings indicate that the biliary excretion of ditekiren and possibly other hydrophobic oligopeptides is mediated, in part, by P-glycoprotein and suggest a
possible physiological role for this hepatic transporter.
This article has been cited by other articles:
|
|
 |
|
  J. Madon, B. Hagenbuch, L. Landmann, P. J. Meier, and B. Stieger Transport Function and Hepatocellular Localization of mrp6 in Rat Liver Mol. Pharmacol., March 1, 2000; 57(3): 634 - 641. [Abstract] [Full Text]
|
|
|
|
|
|
V. Lecureur, D. Sun, P. Hargrove, E. G. Schuetz, R. B. Kim, L.-B. Lan, and J. D. Schuetz Cloning and Expression of Murine Sister of P-Glycoprotein Reveals a More Discriminating Transporter Than MDR1/P-Glycoprotein Mol. Pharmacol., January 1, 2000; 57(1): 24 - 35. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Akhteruzzaman, Y. Kato, H. Kouzuki, H. Suzuki, A. Hisaka, B. Stieger, P. J. Meier, and Y. Sugiyama Carrier-Mediated Hepatic Uptake of Peptidic Endothelin Antagonists in Rats J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1107 - 1115. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Niinuma, Y. Kato, H. Suzuki, C. A. Tyson, V. Weizer, J. E. Dabbs, R. Froehlich, C. E. Green, and Y. Sugiyama Primary active transport of organic anions on bile canalicular membrane in humans Am J Physiol Gastrointest Liver Physiol, May 1, 1999; 276(5): G1153 - G1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kato, S. Akhteruzzaman, A. Hisaka, and Y. Sugiyama Hepatobiliary Transport Governs Overall Elimination of Peptidic Endothelin Antagonists in Rats J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 568 - 574. [Abstract] [Full Text]
|
|
|
|
|
|
S. Akhteruzzaman, Y. Kato, A. Hisaka, and Y. Sugiyama Primary Active Transport of Peptidic Endothelin Antagonists by Rat Hepatic Canalicular Membrane J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 575 - 581. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
